EYETECH PHARMACEUTICALS ENTERS DEAL FOR XALATAN, WORLD’S TOP-SELLING OPHTHALMIC MEDICATION EYETECH PHARMACEUTICALS TO PRESENT AT THE JP MORGAN 21ST ANNUAL HEALTHCARE CONFERENCE PFIZER, EYETECH PHARMACEUTICALS ENTER GLOBAL COLLABORATION FOR POTENTIAL TREATMENT FOR BLINDNESS Eyetech Pharmaceuticals Names Charles Williams as Senior Vice President, Manufacturing Arda Ural Appointed Head of Marketing and Sales at Eyetech Pharmaceuticals Eyetech Completes Patient Enrollment For Two Pivotal Phase III Clinical Trials For Macular Degeneration - Early Completion of Patient Enrollment Triggers $54.2 Million in Funding Dr. Anthony P. Adamis Joins Eyetech Pharmaceuticals to Lead Research Team Eyetech Pharmaceuticals Raises $108.5 Million Through Private Equity Placement Eyetech Pharmaceuticals Signs Research Agreement With Massachusetts Eye and Ear Infirmary Gilead Sciences and Eyetech Pharmaceuticals Announce Exclusive License of Potential New Therapy for Age-Related Macular Degeneration